All publications

Export 162 results:
Author Title Type [ Year(Asc)]
2007
Green H, Tilston P, Fearnhill E, Dunn DT, UK HIV Drug Resistance Database.  2007.  The impact of different definitions on the estimated rate of transmitted HIV drug resistance in the UK. 2nd International Workshop on HIV Transmission, 26-28 August 2007.
Dunn DT, Green H, Fearnhill E.  2007.  Time trends in HIV drug resistance in ART-experienced patients in the UK: impact of improved treatments and boosted protease inhibitors. 13th Annual Conference of the British HIV Association, 25-28 April 2007.
Dunn DT, Pillay D.  2007.  UK HIV drug resistance database: background and recent outputs. J HIV Ther. 12:97-8.
2006
Gifford RJM, de Oliveira T, Rambaut A, Myers R.E, Gale C.V, Dunn DT, Shafer R., Vandamme A.M, Kellam P, Pillay D.  2006.  Assessment of automated genotyping protocols as tools for surveillance of HIV-1 genetic diversity. AIDS. 20:1521-9.
Lewis F, Fearnhill E, Murray R, Pillay D, Dunn DT, Leigh Brown A, UK Collaborative Group on HIV Drug Resistance.  2006.  Bayesian models in the analysis of HIV drug resistance data from the UK HIV Drug Resistance Database. 15th International HIV Drug Resistance Workshop, 13-17 June 2006.
Geretti AM, Sabin CA, Dunn DT, UK HIV Drug Resistance Database and UK Collaborative HIV Cohort Study.  2006.  The H208Y mutation in reverse transcriptase is significantly associated with NRTI exposure, M184V and TAM mutation pathways. 15th International HIV Drug Resistance Workshop, 13-17 June 2006.
Easterbrook P, Welz T, UK HIV Drug Resistance Database.  2006.  Impact of HIV-1 subtype on genotypic resistance to protease inhibitors in the United Kingdom. 13th Conference on Retroviruses and Opportunistic Infections, 5-8 February 2006.
Gifford RJM, Kellam P, Dunn DT, Pillay D, UK HIV Drug Resistance Database.  2006.  The impact of structural and functional constraints acting at the nucleic acid level on the evolution of drug resistance in HIV-1. 15th International HIV Drug Resistance Workshop, 13-17 June 2006.
2005
Pillay D, Green H, Matthias R, Dunn DT, Phillips AN, Sabin CA, Evans B..  2005.  Estimating HIV-1 drug resistance in antiretroviral-treated individuals in the United Kingdom. J Infect Dis. 192:967-73.
Phillips AN, Dunn DT, Sabin CA, Pozniak A, Matthias R, Geretti AM, Clark J, Churchill D, Williams I, Hill T et al..  2005.  Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS. 19:487-94.
Geretti AM, Sabin CA, Dunn DT, Nebbia G, UK HIV Drug Resistance Database and UK Collaborative HIV Cohort Study.  2005.  Mutations at reverse transcriptase (RT) codons G196, Q207, H208, R211 and I214 are associated with drug experience and specific RT mutation patterns. 14th International HIV Drug Resistance Workshop, 7-11 June 2005.
Dunn DT, UK HIV Drug Resistance Database.  2005.  Patterns of thymidine analogue mutations (TAMS) in samples sent for routine HIV drug resistance testing. 14th International HIV Drug Resistance Workshop, 7-11 June 2005.
Grover D, Allen L, Edwards SG, Green H, Copas A, Forsyth S, Pillay D, UK HIV Drug Resistance Database and UK Collaborative HIV Cohort Study.  2005.  Predictors of death and response to therapy in patients with multi (three)-class drug resistant (MDR) HIV in the UK. 14th International HIV Drug Resistance Workshop, 7-11 June 2005.
Cane P A, Chrystie I, Dunn DT, Evans B., Geretti AM, Green H, Phillips AN, Pillay D, Porter K, Pozniak A et al..  2005.  Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ. 331:1368.
Gifford RJM, Pillay D, UK HIV Drug Resistance Database.  2005.  Utilisation of HIV-1 subtype specific consensus sequences to explore treatment related mutational patterns within and between subtypes. 14th International HIV Drug Resistance Workshop, 7-11 June 2005.
Grover D, Allen L, Pillay D, Green H, Copas A, Forsyth S, Edwards SG, UK HIV Drug Resistance Database and UK Collaborative HIV Cohort Study.  2005.  Virological and clinical outcomes in patients with multi (three)-class drug resistance (MDR). 11th Annual Conference of the British HIV Association, 20-23 April 2005.
2004
Pillay D, Green H, Gazzard B, Pozniak A, Matthias R, Johnson M, Churchill D, Fisher M, Hill T, Geretti AM et al..  2004.  Estimating resistance in drug experienced patients in the UK. 13th International Drug Resistance Workshop, 8-12 June 2004.
Phillips AN, Dunn DT, Sabin CA, Pozniak A, Matthias R, Geretti AM, Clark J, Churchill D, Williams I, Hill T et al..  2004.  Long term risk of development of drug resistance after starting antiretroviral therapy in routine clinical practice. 7th International Congress on Drug Therapy in HIV Infection, 14-17 November 2004.
Dunn DT, Green H, Matthias R, Woodburn P, Gifford RJM, Chrystie I, Zuckerman M., Geretti AM, Loveday C, Clark J et al..  2004.  Prevalence of reduced drug susceptibility in treatment-naive patients in the UK. 13th International Drug Resistance Workshop, 8-12 June 2004.
Phillips AN, Dunn DT, Sabin CA, Pozniak A, Matthias R, Geretti AM, Clark J, Churchill D, Williams I, Hill T et al..  2004.  Risk of development of drug resistance in patients starting antiretroviral therapy with three or more drugs in routine clinical practice. 13th International Drug Resistance Workshop, 8-12 June 2004.